Management of inter-episodic periods in patients with bipolar disorder

Expert Review of Neurotherapeutics

Volumn 16, Issue 6, 2016, Pages 659-670

  Samalin, Ludovic ^a,b   Murru, Andrea ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Bipolar disorder; clinical staging; guidelines; inter episodic phase; long term treatment; maintenance treatment; pharmacological treatment; psychological treatment

Indexed keywords

NEUROLEPTIC AGENT;

ANXIETY DISORDER; BIPOLAR DISORDER; BIPOLAR II DISORDER; CLINICAL FEATURE; COMORBIDITY; HUMAN; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MONITORING; PHYSIOTHERAPY; PRACTICE GUIDELINE; PROPHYLAXIS; PSYCHOSOCIAL CARE; REVIEW; SUBSTANCE ABUSE; SUICIDE; TREATMENT DURATION; TREATMENT INDICATION;

BIPOLAR DISORDER; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84964434607     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1080/14737175.2016.1176530     Document Type: Review

References (80)

1. K.R.Merikangas, R.Jin, J.P.He, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–251.
2. I.Grande, M.Berk, B.Birmaher, et al. Bipolar disorder. The Lancet. 2015;387:1561–1572.
3. World Health Organisation. The global burden of disease: 2004 update. Geneva: WHO press; 2008.
4. F.Angst, H.H.Stassen, P.J.Clayton, et al. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167–181.
5. R.W.Licht, P.Vestergaard, A.Brodersen Long-term outcome of patients with bipolar disorder commenced on lithium prophylaxis during hospitalization: a complete 15-year register-based follow-up. Bipolar Disord. 2008;10:79–86.
6. C.De Dios, E.Ezquiaga, J.L.Agud, et al. Subthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients. J Affect Disord. 2012;143:160–165.
7. L.L.Judd, P.J.Schettler, H.S.Akiskal, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry. 2008;65:386–394.
8. M.A.Frye, L.N.Yatham, J.R.Calabrese, et al. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. J Clin Psychiatry. 2006;67:1721–1728.
9. I.Soreca, E.Frank, D.J.Kupfer. The phenomenology of bipolar disorder: what drives the high rate of medical burden and determines long-term prognosis? Depress Anxiety. 2009;26(1):73–82.
10. J.Sanchez-Moreno, A.Martinez-Aran, R.Tabares-Seisdedos, et al. Functioning and disability in bipolar disorder: an extensive review. Psychother Psychosom. 2009;78:285–297.
11. B.Sole, C.M.Bonnin, C.Torrent, et al. Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand. 2012;125:309–317.
12. C.M.Bonnin, A.Martinez-Aran, C.Torrent, et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord. 2010;121:156–160.
13. L.Samalin, P.M.Llorca, B.Giordana, et al. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). J Affect Disord. 2014;159:94–102.
14. L.Samalin, I.De Chazeron, E.Vieta, et al. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. Bipolar Disord. 2016;18:164–173.
15. G.M.MacQueen, L.T.Young, R.T.Joffe. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand. 2001;103:163–170.
16. L.V.Kessing. Recurrence in affective disorders. Br J Psychiatry. 1998;172:23–28.
17. P.P.Roy-Byrne, R.M.Post, T.W.Uhde, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl. 1985;317:1–34.
18. L.Samalin, M.Reinares, I.De Chazeron, et al. Course of residual symptoms according to the duration of euthymia in remitted bipolar patients. Acta Psychiatr Scand. 2016. [cited 2016 Mar30]. doi:10.1111/acps.12568.
19. E.B.Dennehy, T.Suppes, A.J.Rush, et al. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the texas medication algorithm project. Psychol Med. 2005;35:1695–1706.
20. R.H.Perlis. Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr Med Res Opin. 2007;23:467–475.
21. L.Samalin, S.Guillaume, C.Auclair, et al. Adherence to guidelines by French psychiatrists in their real world of clinical practice. J Nerv Ment Dis. 2011;199(4):239–243.
22. E.Frank, R.F.Prien, J.B.Jarrett, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851–855.
23. M.Tohen, E.Frank, C.L.Bowden, et al. The International Society for bipolar disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453–473.
24. G.M.Goodwin, P.M.Haddad, I.N.Ferrier, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016. [cited 2016 Mar15]. doi:10.1177/0269881116636545.•• Most recent and comprehensive British guidelines for treating bipolar disorder.
25. National Institute for Health and Care Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents in primary and secondary care (Clinical Guideline 185); 2014; [cited 2016 Feb02]. Available from: www.nice.org.uk/guidance/cg185•• Meaningful guidelines from the British national agency for the management of bipolar disorder.
26. Management of Bipolar Disorder in Adults. Malaysia Health Technology Assessment Section (MaHTAS). Ministry of Health Malaysia, Putrajaya, Malaysia; 2014; [cited 2016 Feb02]. Available from: www.moh.gov.my/English.php/pages/view/217
27. H.Grunze, E.Vieta, G.M.Goodwin, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.•• Comprehensive international guidelines for the long-term treatment of bipolar disorders focusing on the pharmacological treatment.
28. L.N.Yatham, S.H.Kennedy, S.V.Parikh, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.•• Last update of one of the most useful evidence-based guidelines for the management of bipolar disorder.
29. L.N.Yatham, S.H.Kennedy, C.O’Donovan, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5–69.
30. G.S.Malhi, D.Bassett, P.Boyce, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206.•• Recent and comprehensive published guidelines for the treatment of major depressive disorder and bipolar disorder.
31. M.F.Bravo, G.Lahera, L.Lalucat, et al. Clinical practice guideline on bipolar disorder: drug and psychosocial therapy. Asociación Española de Neuropsiquiatría. Med Clin (Barc). 2013;141(7):305.e1-e10.
32. Guía de Práctica Clínica sobre Trastorno Bipolar. Ministerio de Sanidad, Servicios Sociales e Igualdad, Universidad de Alcalá. Madrid, Asociación Española de Neuropsiquiatría; 2005; [cited 2016 Feb02]. Available from:www.guiasalud.es/GPC/GPC_510_Trastorno_Bipolar_compl.pdf
33. L.Samalin, S.Guillaume, P.Courtet, et al. French Society for Biological Psychiatry and Neuropsychopharmacology task force. Formal consensus for the treatment of bipolar disorder: an update (2014). Encephale. 2015;41(1):93–102.
34. P.M.Llorca, P.Courtet, P.Martin, et al. Screening and management of bipolar disorders: results. Encephale. 2010;36(Suppl 4):S86–102.
35. P.M.Llorca, P.Courtet, P.Martin, et al. Screening and management of bipolar disorders: methodology. Encephale. 2010;36(Suppl 4):S79–85.
36. R.M.Post, G.S.Leverich, R.W.Kupka, et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry. 2010;71:864–872.
37. C.De Dios, A.González-Pinto, J.M.Montes, et al. Predictors of recurrence in bipolar disorders in Spain (PREBIS study data). J Affect Disord. 2012;141(2–3):406–414.
38. L.V.Kessing, P.K.Andersen. Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Curr Psychiatry Rep. 2005;7(6):413–420.
39. M.Berk, A.Brnabic, S.Dodd, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011;13:87–98.
40. C.López-Jaramillo, J.Lopera-Vásquez, A.Gallo, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord. 2010;12(5):557–567.
41. M.Berk, K.Hallam, G.S.Malhi, et al. Evidence and implications for early intervention in bipolar disorder. J Ment Health. 2010;19(2):113–126.
42. P.V.Magalhaes, S.Dodd, A.A.Nierenberg, et al. Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Aust N Z J Psychiatry. 2012;46:1058–1067.
43. C.L.Bowden, J.R.Calabrese, S.L.McElroy, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57:481–489.
44. A.Murru, F.Colom, A.Nivoli, et al. When should mood stabilizers be withdrawn due to lack of efficacy? Some methodological considerations. Eur Psychiatry. 2011;26(3):183–186.
45. J.R.Geddes, G.M.Goodwin, J.Rendell, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–395.
46. A.Murru, D.Popovic, I.Pacchiarotti, et al. Management of adverse effects of mood stabilizers. Curr Psychiatry Rep. 2015;17(8):603.
47. D.M.Novick, H.A.Swartz, E.Frank. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord. 2010;12(1):1–9.
48. M.Pompili, X.Gonda, G.Serafini, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15(5):457–490.
49. I.Pacchiarotti, D.J.Bond, R.J.Baldessarini, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249–1262.•• Comprehensive review and consensus experts on the use of antidepressant in bipolar disorder.
50. G.Petrides, K.G.Tobias, C.H.Kellner, et al. Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature. Neuropsychobiology. 2011;64:129–140.
51. M.Reinares, J.Sánchez-Moreno, K.N.Fountoulakis. Psychosocial interventions in bipolar disorder: what, for whom, and when. J Affect Disord. 2014;156:46–55.
52. D.H.Lam, S.H.Jones, P.Hayward. Cognitive therapy for bipolar disorder: a therapist’s guide to concepts, methods and practice. Hoboken, NJ: John Wiley & Sons; 2010.
53. F.Colom, E.Vieta. Psychoeducation manual for bipolar disorder. Cambridge: Cambridge University Press; 2006.
54. D.J.Miklowitz. Bipolar disorder: a family-focused treatment approach. New York, NY: Guilford Press; 2008.
55. E.Frank. Treating bipolar disorder: a clinician’s guide to interpersonal and social rhythm therapy. New York, NY: Guilford Press; 2005.
56. C.Torrent, M.Bonnin Cdel, A.Martínez-Arán, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry. 2013;170(8):852–859.
57. F.Ng, O.K.Mammen, I.Wilting, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559–595.
58. E.Vieta, T.Suppes. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10:163–178.
59. C.Schneck, D.Miklowitz, J.Calabrese, et al. Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the systematic treatment enhancement program. Am J Psychiatry. 2004;161:1902–1908.
60. R.S.McIntyre, A.Schaffer, S.Beaulieu. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Ann Clin Psychiatry. 2012;24(1):2–3.
61. A.Schaffer, D.McIntosh, B.I.Goldstein, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24(1):6–22.
62. S.Beaulieu, S.Saury, J.Sareen, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry. 2012;24(1):38–55.
63. R.D.Weiss, M.L.Griffin, M.E.Kolodziej, et al. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry. 2007;164:100–107.
64. L.Samalin, A.Tremey, P.-M.Llorca. Quetiapine extended release for the treatment of bipolar disorder. Expert Rev Neurother. 2014;14(9):987–1005.
65. A.H.Young, S.L.McElroy, B.Olausson, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15(2):96–112.
66. R.H.Weisler, W.A.Nolen, A.Neijber, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011;72(11):1452–1464.
67. T.Suppes, E.Vieta, S.Liu, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009;166(4):476–488.
68. E.Vieta, T.Suppes, I.Eggens, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008;109(3):251–263.
69. D.Popovic, M.Reinares, J.M.Goikolea, et al. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012;22(5):339–346.
70. D.Popovic, C.Torrent, J.M.Goikolea, et al. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand. 2014;129(5):366–374.
71. J.D.Amsterdam, L.Lorenzo-Luaces, I.Soeller, et al. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. J Affect Disord. 2015;185:31–37.
72. J.D.Amsterdam, J.Shults. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792–800.
73. D.Popovic, M.Reinares, J.Scott, et al. Polarity index of psychological interventions in maintenance treatment of bipolar disorder. Psychother Psychosom. 2013;82(5):292–298.
74. E.Vieta. Staging and psychosocial early intervention in bipolar disorder. Lancet Psychiatry. 2015;2:483–485.
75. E.Frank, V.L.Nimgaonkar, M.L.Phillips, et al. All the world’s a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective. Mol Psychiatry. 2015;20(1):23–31.
76. I.Grande, P.V.Magalhães, I.Chendo, et al. Staging bipolar disorder: clinical, biochemical, and functional correlates. Acta Psychiatr Scand. 2014;129(6):437–444.
77. F.Kapczinski, P.V.Magalhaes, V.Balzanza-Martinez, et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force report. Acta Psychiatr Scand. 2014;130:354–363.•• International report on the concept of clinical staging in bipolar disorder.
78. R.P.Garay, P.M.Llorca, A.H.Young, et al. Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discov Today. 2014;19(11):1792–1800.
79. P.L.O’Brien, C.P.Thomas, D.Hodgkin, et al. The Diminished Pipeline for Medications to Treat Mental Health and Substance Use Disorders. Psychiatr Serv. 2014;65(12):1433–1438.
80. E.Vieta, C.Torrent, A.Martinez-Aran. Functional remediation for bipolar disorder. Cambridge: Cambridge University Press; 2014.